pomalidomide has been researched along with sirolimus in 3 studies
| Studies (pomalidomide) | Trials (pomalidomide) | Recent Studies (post-2010) (pomalidomide) | Studies (sirolimus) | Trials (sirolimus) | Recent Studies (post-2010) (sirolimus) |
|---|---|---|---|---|---|
| 623 | 121 | 552 | 20,711 | 2,368 | 11,516 |
| Protein | Taxonomy | pomalidomide (IC50) | sirolimus (IC50) |
|---|---|---|---|
| Bile salt export pump | Homo sapiens (human) | 10 | |
| ATP-dependent translocase ABCB1 | Homo sapiens (human) | 1.25 | |
| Cytochrome P450 3A4 | Homo sapiens (human) | 2 | |
| Cytochrome P450 2C9 | Homo sapiens (human) | 2 | |
| Peptidyl-prolyl cis-trans isomerase FKBP1A | Mus musculus (house mouse) | 0.001 | |
| Cytochrome P450 2C19 | Homo sapiens (human) | 4 | |
| Serine/threonine-protein kinase mTOR | Homo sapiens (human) | 0.0897 | |
| Peptidyl-prolyl cis-trans isomerase FKBP1A | Homo sapiens (human) | 0.0042 | |
| Regulatory-associated protein of mTOR | Homo sapiens (human) | 0.225 | |
| Target of rapamycin complex subunit LST8 | Homo sapiens (human) | 0.225 | |
| Broad substrate specificity ATP-binding cassette transporter ABCG2 | Homo sapiens (human) | 1.9 | |
| Solute carrier organic anion transporter family member 1B1 | Homo sapiens (human) | 1.1 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 2 (66.67) | 2.80 |
| Authors | Studies |
|---|---|
| Santos, FP; Verstovsek, S | 1 |
| Cao, H; Lu, J; Mao, B; Yan, P; Zhang, Q; Zhao, D; Zhao, P | 1 |
| Brander, DM; Ding, W; Gui, M; He, W; Huntington, SF; Iqbal, M; Kearney, AS; Koehler, AB; Leis, JF; Mato, AR; McKinlay, TP; Moustafa, MA; Rosenthal, AC; Schuster, SJ; Tun, HW | 1 |
1 review(s) available for pomalidomide and sirolimus
| Article | Year |
|---|---|
Breakthroughs in myeloproliferative neoplasms.
Topics: Animals; Everolimus; Humans; Immunologic Factors; Janus Kinase 2; Myeloproliferative Disorders; Nitriles; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Signal Transduction; Sirolimus; Thalidomide | 2012 |
1 trial(s) available for pomalidomide and sirolimus
| Article | Year |
|---|---|
DTRMWXHS-12, a novel Bruton tyrosine kinase inhibitor, in combination with everolimus and pomalidomide in patients with relapsed/refractory lymphomas: An open-label, multicenter, phase 1a/1b study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Everolimus; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma; Middle Aged; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Sirolimus; TOR Serine-Threonine Kinases; Treatment Outcome; Tyrosine Kinase Inhibitors | 2023 |
1 other study(ies) available for pomalidomide and sirolimus
| Article | Year |
|---|---|
Design, Synthesis, and Biological Evaluation of mTOR-Targeting PROTACs Based on MLN0128 and Pomalidomide.
Topics: Humans; Protein Kinase Inhibitors; Proteolysis; Sirolimus; TOR Serine-Threonine Kinases | 2023 |